UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-KSB

(Mark One)

[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

             For the fiscal year ended December 31, 2007

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

    For the transition period from _____________ to _____________

                         Commission file number 000-9519


                            REGENT TECHNOLOGIES, INC.
                         ------------------------------
                 (Name of small business issuer in its charter)

           Colorado                                      84-0807913
       ---------------                               -----------------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
 incorporation or organization)

6727 Hillcrest Ave., Suite E, Dallas, TX                   75205
(Address of principal executive offices)                 (Zip Code)

                     Issuer's telephone number 214-507-9507

         Securities registered under Section 12(b) of the Exchange Act:

   Title of each class             Name of each exchange on which registered
   -------------------             -----------------------------------------
         None                                        None

         Securities registered under Section 12(g) of the Exchange Act:

                             $0.01 pv common stock
                                (Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [ ] No [X]

Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [X]

State issuer's revenues of its most recent fiscal year. $0.00

State the aggregate market value of the voting and non-voting common equity held
by non-affiliates computed by reference to the price at which the common equity
was sold, or the average bid and asked price of such common equity, as of a
specified date within the past 60 days. (See definition of affiliate in Rule
12b-2 of the Exchange Act.) - $5,000.


State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:  5,657,456 shares common stock $.01
par value as of March 15, 2008.

                       DOCUMENTS INCORPORATED BY REFERENCE

Form 10-QSB for first, second and third quarter of fiscal year.

Transitional Small Business Disclosure Format (Check one): Yes [ ] No [X]


<PAGE>
                                TABLE OF CONTENTS


Number                   Item in Form 10-KSB                            Page No.
------                   -------------------                            --------

   1     Description of Business                                             3

  1A     Risk Factors                                                        4

   2     Description of Property                                             6

   3     Legal Proceedings                                                   6

   4     Submission of Matters to a Vote of Security Holders                 6

   5     Market for Common Equity and Related Stockholder Matters            7

   6     Management's Discussion and Analysis for Plan of Operation          7

   7     Financial Statements                                               11

   8     Changes in and Disagreements with Accountants on Accounting
         and Financial Disclosure                                           25

  8A(T)  Controls and Procedures                                            25

   9     Directors, Executive Officers, Promoters and Control Persons       26

  10     Executive Compensation                                             28

  11     Security Ownership of Certain Beneficial Owners and Management     28

  12     Certain Relationships and Related Transactions                     30

  13     Exhibits and Reports on Form 8-K                                   30

  14     Principal Accountant Fees and Services                             31

         Signatures                                                         32


                                       2
<PAGE>

                                     PART I

ITEM 1 - DESCRIPTION OF BUSINESS

General

The terms "Company" and "Regent" when used herein mean Regent Technologies,
Inc.  and  its  subsidiaries.   Regent Technologies, Inc., formerly Regent
Petroleum Corporation, was incorporated under the laws of the  State  of
Colorado  on January  18,  1980.   In 1994, new management  redirected  the
Company's core business toward the development of emerging technologies and
the shareholders voted to rename the Company at a meeting held on December 19,
1994. In 1994, the Company acquired SSB Environmental, Inc. (SSB), which was
organized for the purpose of obtaining waste and landfill reclamation contracts.
Effective January 1, 1996, the Company sold 81% of its interest in SSB.  In
September, 1996, the Company entered into a license agreement for the technology
necessary to offer dialup access to the internet. During the fourth quarter of
1996, the Company organized Regent TEL1 Communications, Inc. as a wholly owned
subsidiary  to market its  Internet products to consumer markets.  In the third
quarter of 1997, the Company acquired ConnecTen, L.L.C. as a wholly owned
subsidiary to  market its dedicated  Internet services to professionals and
corporations.  During the first quarter of 1998, the Company acquired Channel
Services, LC, to expand its telecommunications products to include wireless
telephone services.  During the first quarter of 1998, the Company organized
Regent Digital Imaging, Inc. to offer digital printing and prepress services
with access available via the Internet.  At the shareholders meeting on March 4,
1998, the shareholders  approved a 1 for 6 reverse split of the common stock
of the Company.  During 1999, the Company's subsidiary companies were divested
in the ordinary course of business through sales in lieu of foreclosure due to
the Company's creditors seeking repayment for delinquent debt and the inability
to raise capital due to continuing operating losses.  Effective January 1, 1999,
the Company had re-entered the development stage.  In 2003, new management
initiated the process of reclaiming shares of stock issued in 1999 and 2000
without the delivery of adequate consideration to the Company.  During 2005,
management gained control of the necessary information for auditing the books
and records of the Company in order to file delinquent SEC reports.  As of the
date of this Form 10-KSB, all SEC reports are current.

Recent Business Developments

During the first quarter, 2007, the Registrant initiated a new business strategy
to create value for our stockholders by investing in business opportunities that
have a unique technological advantage.  Key elements of our business strategy
include investing in businesses with: (1) the potential of outstanding earning
power and  good  returns  on equity; (2) experienced  management; and (3) a
business plan which  demonstrates a high likelihood for success in a relatively
short period of time.  In March, 2007, the Company formed a Texas corporation as
a wholly owned subsidiary named Regent GLSC Technologies, Inc. ("Regent GLSC").
Regent GLSC was formed to invest in the "global life science commercialization"
process by working with inventors and innovative research teams focused on the
commercialization of medical products.  Regent GLSC's focus is the acquisition
of equity in new product development and long-term participation in future
income streams derived from new products marketed throughout the world. This
strategy includes sitting on the boards of and shaping policy of the acquired
interests to assure the highest prospect of return. Regent GLSC's initial entry
was the purchase of a 10% ownership in MacuCLEAR, Inc. ("MacuCLEAR"), a company
organized by Texas A & M University for the development of a treatment of the
eye disease known as dry age-related macular degeneration. The equity ownership
in MacuCLEAR was financed through the sale of preferred stock in Regent GLSC.
See ITEM 6 - Management's Discussion and Analysis for Plan of Operation" for
the details and status of the MacuCLEAR investment.

                                       3
<PAGE>
Employees

The Company currently has one full-time employee. The Company also utilizes
outside professionals with the number varying according to project requirements.

Transfer Agent

On December 28, 2007, the Company appointed Securities Transfer Corporation
as the Transfer Agent to handle securities transactions for the Company.
The address for Securities Transfer Corporation is 2591 Dallas Parkway, Suite
102, Frisco, Texas 75034.

ITEM 1A - RISK FACTORS

Risk of Limited Operating History

Regent GLSC is a newly organized venture.  Although management has
extensive experience in the industry and management of secured assets,
there can be no assurance that the Company will be profitable or that
the Company's business will be successful in the future.  To date the
Company has no revenues from operations and no assets and the Company's
auditors have prepared the accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going
concern.

Reliance on Key Personnel

The success of the Company's operations is heavily dependent upon the
continued active participation of its executive Officers and Directors.
Should they be unable or unwilling to continue active participation in
the Company's affairs, the future viability of the Company would be
materially adversely affected unless competent replacement(s) could be
promptly hired.

Capital Requirements

We may receive from the Regent GLSC Offering maximum  net proceeds of
$1,250,000, which we believe will be sufficient to implement our initial
plan of operation.  Without the proceeds of the Regent GLSC Offering, we
will have only minimal capital with which to provide investments and will
be limited in our operations.  If less than the maximum financing Regent
GLSC Offering is not available to us, the Company will continue to seek
investment capital but our activities may be materially and adversely
affected.

Unspecified Investments and Acquisitions

The Company will use all of the net proceeds from the Regent GLSC Offering
and other Company Offerings to acquire existing business entities or an
equitable interest of business entities to enhance the Company's ability
to meet its business objectives.  In this regard, management of the Company
has complete authority and responsibility for evaluating and choosing the
assets for which the Company will provide investment.  Purchasers of the
Securities will not have an opportunity to evaluate for themselves all the
assets in which capital of the Company will be invested, or the terms of
such investments.
                                        4
<PAGE>
Competition

The Company has numerous competitors in its investing operations, including
angels and venture capital companies, which may lend or invest on an unsecured,
as well as on a secured basis.  In connection with its financing of medical
research groups, competitors include numerous drug and technology companies.
The Company expects that new competitors will enter the market for acquiring
promising assets.  Some of the competitors of the Company may have greater and
more sophisticated development, financial, marketing, distribution and other
resources than the Company.  Increased competition may have a material adverse
effect on the profitability of the Company.

Risks Related to Improper Assessment of the Acquired Asset's Estimated Value

Evaluations of new technologies and invention groups are based on best  effort
investigation of the research focus, the team strength and the potential market
prospects.   In this regard, the recovery of  the amount advanced, as well as
realization of a profit on marketing or licensing of a new product is dependent
on the initial  assessment or  appraisal of  the invention's  estimated  value.
No assurance can be given that  such appraisals  will in  any or all cases, be
accurate.  Also, since an appraisal fixes its value at a  given  point in time,
subsequent events could adversely affect  the prospect of  financial  recovery.
Such subsequent events may include  nationwide, statewide or  local  economic,
demographic,  regulatory,  medical or  other  technical  and  pharmaceutical
developments.  Denial of  FDA  approval, an  unforeseen  ill effect  of  the
formulation or unwillingness of medical practitioners to employ the new drug or
medical device could adversely affect the  value of a  particular investment.
The Company will not necessarily be able to predict with any certainty whether
any of these events will occur after an investment is made. Improper assessment
of the market value of the invention can result in reduced marketability of the
asset and resale of the asset for an amount less  than  the amount  advanced.
Although the skill of the Company management team lead us to believe that it can
expertly identify and evaluate innovations, no assurances can be given that such
innovations will produce a profit.

Diversification Risk

The Company may not be able to diversify its asset portfolio either financially
or substantively.   If the Company does not raise  sufficient funds through the
Regent GLSC Offering or other Offerings, the  Company may  have a  small amount
of money with which to invest in product development. An investment of a smaller
sum of money will likely result in the acquisition  of fewer assets  and  less
diversification of the GLSC portfolio.  In addition, the  Company contemplates
that the majority of its  investments for  GLSC technology  will  be secured by
inventions in the medical sector.  If substantial portions of  our  investments
are secured by assets involved in medical treatment, a  downturn  in that sector
of the economy would  more greatly affect us than if our lending  and  investing
were more industrially diversified.  Adverse changes in  national  political /
regulatory action toward medical treatment or toward other sectors relating to
the medical industry in   which innovative  products are to be  marketed would
likely have an adverse impact on the profitability of the asset invested in.

                                        5
<PAGE>
Risks Associated with Operations

If expenses  of operations  exceed the  anticipated income  of operations, the
Company may be required to dispose of the assets on disadvantageous terms, if
necessary, to raise capital.  In the event operations do not generate sufficient
operating income to pay all of the operating expenses, taxes and debt service
requirements, the Company may sustain a loss of its investment.  There can be no
assurance that the Company will not incur operating deficits.

Government Regulation

Development of new drugs and  medical  procedures  are  subject to  extensive
regulation, supervision and  licensing under various federal, state and local
statutes, ordinances and regulations.  These  statutes prescribe, among  other
things, extent of testing and proof required to market a medical device or drug.
Governmental regulators have broad discretionary authority to refuse to grant a
license or to suspend or revoke any or all existing licenses of licensees under
common control if it is determined that any such licensee has violated  any law
or regulation or that the management of any  such licensee is not  suitable to
bring such a product to market.  In addition, there  can be no  assurance that
additional state or federal statutes or regulations will not be enacted at some
future date which could inhibit the team's  ability to  grow a  product market,
conduct further research, bring  new products  to market, or  prohibit or more
stringently regulate the sale of certain goods, any of which could significantly
adversely affect the Company's prospects.

ITEM 2 - DESCRIPTION OF PROPERTY

Offices

The Company currently does not occupy formal office facilities but uses space
on an as needed basis without charge provided by a former officer of the Company
and as of 2004 by a business associate.  The fair rental value of this space
provided was not and is currently not material.  Management believes that the
Company will establish formal office space in 2008.

ITEM 3 - LEGAL PROCEEDINGS

During 2001, stockholder David Nelson initiated a lawsuit against the Company
and management of the Company for issuing shares of common stock without
consideration. The case was ordered for mediation and on February 27, 2003, the
case was settled with former management concurring that 7,331,504 shares were
issued without consideration and should be cancelled.  Also, as part of the
mediation settlement, it was agreed that certain shares previously owned by the
father of the President, Richard Straza and the Straza family members and legal
entities (the Straza Shares) would be returned and cancelled and that the
Company would be indemnified against claims arising from the Straza Shares.

On November 2, 2005, W. T. Skip Leake initiated litigation in the 101st State
District Court of Dallas County against the Company and the Company's stock
transfer agent seeking a declaratory judgment for the release of 1,000,000
shares of the 7,331,504 shares which former management states were issued
without consideration.  The Company filed a counter-claim against 35
defendants for a declaratory judgment that all disputed shares are void for
lack of Director approval and failure of consideration and that the 7,331,504
shares and the Straza Shares should be cancelled.  At December 31, 2007, the
Company settled the remaining claims resulting in the cancellation of the
recovery of 14,929,838 shares of common stock of Registrant.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were presented for a vote to the shareholders of Regent.

                                       6
<PAGE>
                                 PART II


ITEM 5 - MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The Company's Common Stock is traded in the "pink-sheets" under the symbol
"REGT."  For the period ended December 31, 2007, security dealers did not
report high and low bid quotations.  The Company's stock has traded in a
range of $.0001 and $.1875 for the years ended December 31, 2007 and 2006.

The  Company has not declared any cash dividends on its Common Stock since
its inception.   The  Company  currently intends to retain any future
earnings to finance the growth of the  business and, therefore, does not
anticipate  paying  any cash  dividends in the foreseeable future.  As of
December 31, 2007,  the  approximate  number  of  record  holders  of   the
Company's Common Stock was 2,100.

ITEM 6 - MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Forward Looking Statements

The following discussion and analysis should be read in conjunction with the
financial statements and notes thereto included elsewhere in this report on
Form 10-KSB for Regent Technologies, Inc. ("Regent" or "We" or the "Company").
This report contains certain statements that are "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933, as amended
(the "Securities Act"), and Section 21E of the Securities Exchange Act of
1934, as amended (the "Exchange Act").  Those statements, among other things,
include the discussions of the Company's expectations set forth below. Although
the Company believes that the expectations reflected in the forward looking
statements are reasonable, management can give no assurance that such
expectations will prove to have been correct. Generally, forward looking
statements relate to business plans or strategies, projected or anticipated
benefits or other consequences of such plans or strategies, or projections
involving anticipated revenues, expenses, earnings, levels of capital
expenditures, liquidity or indebtedness, ability to raise working capital, or
other aspects of operating results or financial position. Although not always
the case, forward looking statements can be identified by the use of words
such as "believes", "expects", "intends", "projects", "anticipates",
"contemplates", or "estimates".

Plan of Operation

As a development  stage company, we  have  focused on  the identification,
acquisition and development of new technologies and products which we believe
believe have the potential for commercialization.  We conduct our operations
through our subsidiary, Regent GLSC Technologies, Inc. ("Regent GLSC").  The
Company expects to form one or more additional subsidiary companies for future
operation.  Our strategy is to initially acquire rights to technologies and
products that are being developed by third parties and are at or near the final
stages of commercialization.  We do not plan to limit the scope of our subsi-
diary operations and are currently considering investments in new technologies
related to the exploration of oil and gas, renewable energy and environmental
reclamation.

                                   7
<PAGE>
Since  inception  the Registrant has funded  operations through short-term
borrowings and equity investments in order  to meet  obligations.  Our  future
operations are dependent  upon  external funding and our ability  to  increase
revenues and reduce expenses. Management believes that sufficient funding will
be available from additional related party borrowings and private placements to
meet our business  objectives  including  anticipated cash  needs for  working
capital, for a reasonable period of time.


  Global life science commercialization - GLSC

Many factors are raising significant new opportunities in the development of
innovative products for dealing with human health and well-being.  One of the
noticeable stimulants to recent  medical innovation arises from remarkable
advances in knowledge within  the fields of biotechnology and nanotechnology.
However, perhaps the most profound force confronting the industry today is the
demographic shift that the US and other developed nations are experiencing.
Aging populations in this country, Japan and Europe in particular, are expected
to double demands on medical and health-care institutions and related products
over the next decade.  A third major force, particularly behind the development
of new pharmaceuticals related to aging, is the large grouping of branded drug
patents that will be expiring in the next few years.

Drug industry analysts indicate that over the next two years, nearly half of
the industry's top drugs valued at $100 billion in sales will lose their patent
protection and not be replaced by major firms.  Declining pharmaceutical share
values have reflected that prospect and the already weak trends in branded drug
sales.  The resulting sense of urgency and dramatic escalations in the internal
costs of discovering new proprietary drugs has caused a shift in the development
strategies of major pharmaceutical firms toward hunting for new product that is
being developed  outside their laboratories.  As a  consequence,  sizeable
investment is  being  made by  these  firms into  the acquisition of promising
licenses with independent research teams throughout the country.  The Company
is focused on funding the best of these teams in both drugs and medical
technology that are in the final stages of product development and proof-of-
product testing in preparation of offering production and marketing licenses.

  Regent GLSC Technologies, Inc.

The Company  formed Regent GLSC Technologies, Inc. as a  subsidiary for the
purpose of participating in the global life science commercialization process.
The mission of Regent GLSC  is to identify  high-prospect and  high-profit
candidates in the life science industry for near-term commercialization.  The
strategy of Regent GLSC is  to secure  advantage gained  from  exceptional
opportunities emerging from new conditions in the pharmaceutical industry and
from unique developments in medical science.  Despite the sizeable funds
directed by major pharmaceutical and technology companies for the development
of new drugs and medical devices, many of the most significant advances in
those products are being made by independent and university-based research
teams.  In those instances, very attractive opportunities arise particularly
for investment groups served by entrepreneurial teams.  Most academic and
independent researchers capable of focusing on innovative work are not well
suited for capitalizing and preparing their products for either licensing or
direct marketing.  Great benefits are gained by the research team that chooses
to join forces with a funding and development group such as Regent GLSC which
is able to implement business plans and marketing strategies suited for the
medical industry.  On April 17, 2007, Regent GLSC acquired its initial entry
into the GLSC market with the purchase of shares of Convertible Preferred
Stock of MacuCLEAR, Inc. through the issuance of Regent GLSC Preferred
Stock (Note 2.).
                                       8
<PAGE>
  About MacuCLEAR, Inc.

MacuCLEAR, Inc. was formed by Texas A & M University as a drug discovery and
development company focused on treating disorders of the eye.  MacuCLEAR has
the exclusive license for a platform technology for preventing the progression
of Age Related Macular Degeneration ("AMD").  Specifically MacuCLEAR has
licensed a proprietary treatment for the "Dry" form of AMD from Texas A & M
University.  MacuCLEAR has the exclusive license for a technology preventing the
progression of Age Related Macular Degeneration ("AMD") with the potential of
reversing the effect of AMD.  Specifically MacuCLEAR has licensed a proprietary
treatment for the "Dry" form of AMD.  The solution is delivered in eye drop form
to restore choroidal blood flow and control inflammation in the macula. The core
component of this novel solution has been used clinically in other applications
and is known to be safe.  Therefore, MacuCLEAR is eligible for an abbreviated
FDA approval process. AMD is the leading cause of blindness for people over the
age of 50.  There are an estimated 1.8 Million new cases of "Dry" and 200,000
"Wet" each year.  These numbers double for  global estimates.  The total U.S.
market potential is $18 billion based on current market for treatments for the
10% who have wet AMD. The potential MacuCLEAR revenues are $1.5 billion in five
years from licensing fees, milestone payments and royalties.

MacuCLEAR is headed by an executive team of business and life science
professionals with significant industry experience.  Philip G. Ralston is the
CEO of MacuCLEAR and the President of Regent GLSC.  He is a seasoned life
science industry professional with Fortune 200, and mid-size private and public
company experience.  He has started four companies and holds 18 patents on
various products.

Financial Condition

The Company did not have revenues from operations in each of the last two fiscal
years.  The Company  is not current  on  its  trade  payables  including amounts
owed to stockholders and continues to  raise  monies  as needed through proceeds
from the sale of the Company's restricted Common Stock or from short term loans
from individuals.

As of December 31,2007, the Company had a cash balance of $20. The Company has
financed its operations primarily through cash on hand and stock issuances
during the fiscal years ended 2007 and 2006.

Net cash flows used in operating activities was $29,755, for the fiscal period
ending December 31, 2007 compared to net cash flows used of $16,469 for the same
period in 2006, primarily due to costs related to the Regent GLSC formation and
the Regent GLSC investments.  The  Company intends to seek additional funds from
shareholders and third parties to finance the Company's operations.

                                        9
<PAGE>
Net cash provided by financing activities was $379,600 for the fiscal period
ending December 31, 2007, compared to $16,100 for the same period in 2006. The
Company has financed its operations primarily from stock issuances. Regent GLSC
raised $325,000 of capital through  the sale of 65,000 shares of it Series A
Convertible Preferred Stock  received under an initial closing on April 18, 2007
with subsequent closings through February 20, 2008.

The Company is not performing any product research and development at this time
and it is not expected to purchase equipment or incur significant changes in the
number of employees.

Related Party Transactions

Related party transactions are in the normal course of operations and are
recorded at amounts established and agreed between the related parties.

During the periods ended December 31, 2007 and 2006, the President and
directors provided services to the Company for no cash compensation.
On November 26, 2007, the Board of Directors approved Restricted Stock Awards
for each Director as partial consideration for service as Directors of the
Company and a Company subsidiary.  Each grant is for up to 500,000 shares of
the Company's restricted common stock issued as Rule 144 securities. The grants
will vest over 36 months from the date of first service as a Director which
resulted in the grant of 500,000 shares to the President and 347,223 shares
to the remaining Directors.

The Company's administrative office is located at 6727 Hillcrest Ave., Suite E,
Dallas, Texas, 75205.  These  premises are  owned by a  private  corporation
controlled by an investor in the Series A Preferred Stock of Regent GLSC.  The
Company does not pay monthly rent.

The Company has borrowings under notes payable to NR Partners, a partnership of
which the President and a director, David Ramsour, are the partners. The notes
have a maturity of December 31, 2008 with a maximum of $100,000.  The notes bear
interest at the rate of eight and one half percent per annum.  The borrowings
have been used to pay expenses related to professional and transfer agent fees.
At December 31, 2008, the Company had an outstanding note payable of $89,800
to NR Partners.  In addition, the Company borrowed $5,000 from Phil Ralston on
similar terms and conditions as the NR Partners note.

Off-Balance Sheet Arrangements

As of the date of this report, we do not have any off-balance sheet arrangements
that have or are reasonably likely  to have a current or future effect on our
financial condition, changes in  financial  condition,  revenues or  expenses,
results of operations, liquidity, capital expenditures or capital resources that
are material to investors.  The term "off-balance sheet arrangement" generally
means any transaction, agreement or other contractual arrangement to which an
entity  unconsolidated  with us is a  party, under which we have:  (i) any
obligation arising under a guarantee contract, derivative instrument or variable
interest; or (ii) a retained or contingent interest in assets transferred to
such entity or similar arrangement that serves as credit, liquidity or market
risk support for such assets.

                                        10
<PAGE>
ITEM 7 - FINANCIAL STATEMENTS

TURNER, STONE  & COMPANY, L.L.P
12700 Park Central Drive, Suite 1400
Dallas, Texas 75251

Report of Independent Registered Public Accounting Firm

Board of Directors and Stockholders
Regent Technologies, Inc. and Subsidiary
Dallas, Texas


We have audited the accompanying consolidated balance sheet of Regent
Technologies, Inc. and Subsidiary, (the Company) (a development stage company)
as of December 31, 2007, and the related consolidated statements of operations,
stockholders' equity (deficit), and cash flows for the years ended December 31,
2007 and 2006, and for the period January 1, 1999 through December 31, 2007.
These consolidated financial statements are the responsibility of the Company's
management.  Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States).  Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement.  An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements.  An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation.  We believe that
our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the consolidated financial position
of Regent Technologies, Inc. and Subsidiary at December 31, 2007, and the
results of their operations and cash flows for the years ended December 31,
2007 and 2006, and for the period January 1, 1999 through December 31, 2007
in conformity with accounting principles generally accepted in the United
States of America.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern.  As discussed in Note 1 to
the consolidated financial statements, the Company has no business operations
and has a working capital deficiency, both of which raise substantial doubt
about its ability to continue as a going concern. Management's plans in regard
to these matters are also described in Note 1.  The consolidated financial
statements do not include any adjustments that might result from the outcome
of this uncertainty.



/s/ Turner, Stone & Company, L.L.P.
----------------------------------
March 30, 2008

                                        11
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                           CONSOLIDATED BALANCE SHEET
                               DECEMBER 31, 2007

<TABLE>
<CAPTION>

<S>                                                                      <C>
                                     ASSETS

CURRENT ASSETS
  Cash in bank                                                          $       20
  Settlements and receivable, net of $12,892
     allowance for uncollectible accounts                                        -
                                                                          ---------
Total Current Assets                                                            20

Property and equipment:
   Furniture and fixtures                                                    8,593
   Computer equipment                                                        2,400
                                                                         ---------
                                                                            10,993
   Less accumulated depreciation                                           (10,993)
                                                                         ---------

     Net property and equipment                                                  -

Investments in affiliate                                                   392,956
                                                                         ---------
TOTAL ASSETS                                                            $  392,976
                                                                         =========


                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES
   Accounts payable, trade                                              $   36,170
   Accounts payable, stockholder                                            10,000
   Note payable, related parties                                            94,800
   Accrued interest payable                                                  8,277
                                                                         ---------
      Total Current Liabilities                                            153,747
                                                                         ---------

STOCKHOLDERS' EQUITY (DEFICIT)
   Preferred stock, $.10 par value, 1,000,000
     shares authorized, 65,000 shares issued and
     outstanding, Regent GLSC Technologies, Inc.                           325,000
   Preferred stock, $.10 par value, 30,000,000
     shares authorized, no shares issued and
     outstanding, Registrant                                                     -
   Common stock, $.01 par value, 100,000,000
     shares authorized, 5,657,456 shares
     issued and outstanding                                                 56,575
   Paid-in capital in excess of par                                      3,351,545
   Accumulated deficit (including $141,392
     accumulated since reentering the development stage)                (3,489,391)
                                                                         ---------
     						                           243,729
                                                                          ---------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                    $  392,976
                                                                          =========


 The accompanying notes are an integral part of the consolidated financial statements.

</TABLE>

                                       12
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                       CONSOLIDATED STATEMENTS OF OPERATIONS
                  FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006
                         AND THE PERIOD JANUARY 1, 1999
                            THROUGH DECEMBER 31, 2007

<TABLE>
<CAPTION>

						  				        Cumulative
                                                                                     Since Re-entering
                                                                                     Development Stage
                                                    2007                2006          January 1, 1999
                                                ------------        ------------        ------------
<S>                                            <C>                 <C>                 <C>
Revenues                                          $       -          $       -           $       -

Operating expenses:


  General and administrative                         47,393              22,916             272,637
  Interest                                            6,285              10,001              34,397
                                                   ---------           ---------           ---------
Operating loss                                     ( 53,678)           ( 32,917)           (307,034)
                                                   ---------           ---------           ---------

Gain on extinguishment of debt                       19,665              85,907             124,186
Gain on sale of investment                           41,456                   -              41,456
                                                   ---------           ---------           ---------
Income (Loss) before income taxes                     7,443              52,990            (141,392)

Provisions for income taxes                               -                   -                   -
                                                  ---------           ---------           ---------
Net income (loss)                                 $   7,443           $  52,990           $(141,392)
                                                  =========           =========           =========

Net income (loss) per common share:               $       -           $     .01
                                                  =========           =========

Weighted average share outstanding                5,657,456           4,832,317
                                                  =========           =========


  The accompanying notes are an integral part of the consolidated financial statements.


</TABLE>


                                       13
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
            CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
                  FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006
                         AND THE PERIOD JANUARY 1, 1999
                            THROUGH DECEMBER 31, 2007

<TABLE>
<CAPTION>
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
                                    Preferred Stock                 Common Stock                                          Total
                               -----------------------       -----------------------      Additional                  Stockholders'
                                  Issued                        Issued                       Paid-In      Accumulated      Equity
                                  Shares      Par Value       Shares        Par Value      Capital        Deficit       (Deficit)
                                  ------      ---------       ------        ---------      -------       --------       ---------
<S>                             <C>         <C>          <C>             <C>            <C>           <C>              <C>

Balance at January 1, 1999             -            -     3,643,693       $  36,437       $3,148,871    $( 3,347,999)  $(  162,691)

Issuance of common stock in
  exchange for services
  at $.10 per share                    -            -        50,000             500            4,500               -         5,000

Issuance of common stock upon
  conversion of notes payable
  at $.11 per share                    -            -     1,800,000         18,000           172,000               -       190,000

Issuance of common stock with
  failed consideration                 -            -    50,877,713        508,777       (  508,777)               -             -

Net loss for 1999                      -            -             -              -                -      (   125,005)   (  125,005)

Issuance of common stock for
  settlement of lawsuit
  at $.10 per share                    -            -       140,000          1,400           12,600                -        14,000

Issuance of common stock with
  failed consideration returned
  and cancelled                        -            -   (36,046,209)      (360,462)         360,462                -             -

Net loss for 2000                      -            -             -              -                -      (    19,938)    (  19,938)

Net loss for 2001, 2002 and 2003       -            -             -              -                -                -             -
                                                         ----------       --------        ---------       ----------   ----------
Balance at December 31, 2003           -            -    20,465,197      $ 204,652       $3,189,656     $( 3,492,942)   $(  98,634)

Net loss for 2004                                                 -              -                -      (     7,936)    (   7,936)
                                                         ----------       --------        ---------       ----------    ----------
Balance at December 31, 2004           -            -    20,465,197      $ 204,652       $3,189,656     $( 3,500,878)   $( 106,570)

Issuance of common stock with
  failed consideration returned
  and cancelled                        -            -   (  750,000)      (  7,500)           7,500                 -             -

Cancellation of Treasury Stock         -            -   (   42,876)      (    429)             429                 -             -

Net loss for 2005                      -            -            -              -                -       (    48,946)       48,946)
                                                        ----------       --------        ---------       ----------     ----------
Balance at December 31, 2005           -            -   19,672,321      $ 196,723       $3,197,585      $( 3,549,824)  $   155,516)

Issuance of common stock for debt
  settlement at $.06 per share         -            -       64,000            640            3,200                           3,840

Net income for 2006                    -            -            -              -                -           52,990         52,990
                                                       -----------       --------        ---------       ----------      ----------
Balance at December 31, 2006           -            -   19,736,321      $ 197,363       $3,200,785     $( 3,496,834)   $    98,686)

Issuance of subsidiary
   preferred stock                  65,000  $ 325,000            -              -                -                -        325,000

Issuance of common stock at $.40
  per share as partial
  consideration under GHI, Ltd.
  - MacuCLEAR sale transaction           -          -        3,750             38            1,462                -          1,500

Issuance of common stock with
  failed consideration returned
  and cancelled                          -          -  (14,429,838)     ( 144,298)         144,298                -              -

Return and cancellation of
  common stock for debt
  settlement with Woody, Inc.            -          -     (500,000)        (5,000)           5,000                -              -

Issuance of restricted stock
  awards to directors at
  $.01 per share                         -          -      847,223          8,472                -                -           8,472

Net income for 2007                      -          -            -              -                -     $      7,443           7,443
                                    ------- ---------    ----------      --------        ---------       ----------      ----------

Balance at December 31, 2007        65,000  $ 325,000    5,657,456      $  56,575       $3,351,545     $( 3,489,391)        243,729
                                    ======  =========   ==========       ========        =========       ==========      ==========

The accompanying notes are an integral part of the consolidated financial statements.
</TABLE>

                                        14
<PAGE>
                     REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENT OF CASH FLOWS
                   FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006
                         AND THE PERIOD JANUARY 1, 1999
                            THROUGH DECEMBER 31, 2007
<TABLE>
<CAPTION>
               					  		   		                    Cumulative
                                                                                                Since Re-entering
                                                                                                Development Stage
                                                                 2007               2006          January 1, 1999
                                                             ------------       ------------        ------------
<S>                                                           <C>                 <C>                 <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net income (loss)                                           $   7,443           $  52,990          $ (141,392)
  Adjustments to reconcile net income (loss) to net
   cash used in operating activities:
     Depreciation                                                     -                   -               3,762
     Gain from extinguishment of accounts payable              ( 19,665)           ( 85,907)           (124,186)
     Gain from sale of investment                              ( 41,456)                  -            ( 41,456)
     Note issued for settlement expenses                              -                   -              20,000
     Common stock issued for services                             8,472                   -              13,472
     Common stock issued in legal settlement                          -                   -              14,000
     Decrease in settlements and note receivable                      -                   -               4,800
     Decrease in other assets                                         -                   -               1,967
     Increase in allowance for uncollectible settlements              -                   -              79,892
     Increase (decrease) in accounts payable                     10,065               6,647              46,348
     Increase (decrease) in accounts payable, stockholder             -                   -              10,000
     Increase in accrued liabilities                              5,386               9,801              43,013
                                                              ---------           ---------           ---------
        Net Cash Used In Operating Activities                  ( 29,755)           ( 16,469)           ( 69,780)
                                                              ---------           ---------           ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
  Investment in affiliates                                     (350,000)                  -            (350,000)
                                                              ---------           ---------           ---------
        Net Cash Used in Investing Activities                  (350,000)                  -            (350,000)

CASH FLOWS FROM FINANCING ACTIVITIES:

  Proceeds from sale of Preferred Stock                         325,000                   -             325,000
  Proceeds from note payable - related party                     54,600              16,100              94,800
                                                              ---------           ---------           ---------
        Net Cash Provided By Financing Activities               379,600              16,100             419,800
                                                              ---------           ---------           ---------
Net Increase (Decrease) in Cash                                    (155)               (369)                 20

Cash At Beginning Of Period                                         175                 544                   -
                                                              ---------           ---------           ---------
Cash At End of Period                                         $      20           $     175           $      20
                                                              =========           =========           =========


                      SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
                      --------------------------------------------------------------------

    Issuance of common stock upon conversion
    of notes payable                                          $       -           $   3,840           $ 193,840

    Common stock issued for director stock awards             $   8,472           $       -           $  13,472

    Common stock returned in failed consideration
    and debt settlement                                       $ 149,298           $       -           $ 509,760

    Repayment of note payable transferred directly
    to MacuCLEAR upon sale to GHI, Ltd.                       $ 150,000           $       -           $ 150,000

    Partial sale of MacuCLEAR holdings to GHI, Ltd.           $ 148,500           $       -           $ 148,500

    Issuance of common stock upon MacuCLEAR sale
    to GHI, Ltd.                                              $   1,500           $       -           $   1,500



The accompanying notes are an integral part of the consolidated financial statements.

</TABLE>
                                       15
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

1.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General

Regent Technologies, Inc., (the Company) formerly Regent Petroleum Corporation,
was incorporated on January 18, 1980, in the state of Colorado for the purpose
of exploration  and development of oil and gas properties in the United States.
Activities of the Company up to 1992 were primarily organizational and included
the issuance of equity capital and the acquisition of developed and undeveloped
oil and gas properties that included the formation of Earth Minerals, Inc. in
1991, which was later renamed Regent Industries, Inc. In 1994, the Company
redirected its core activities and acquired SSB Environmental, Inc. (SSB), which
was organized for the purpose of obtaining waste and landfill reclamation
contracts. Effective January 1, 1996, the Company sold 100% of Regent Industries
and 81% of its interest in SSB.  In September, 1996, the Company entered into a
license agreement for the technology necessary to offer dialup access to the
Internet. During the fourth quarter of 1996, the Company organized Regent TEL1
Communications, Inc. as a Nevada corporation and a wholly owned subsidiary to
market its Internet products and services primarily to consumer markets.  In the
third quarter of 1997, the Company acquired ConnecTen, L.L.C. as a wholly owned
subsidiary to market its dedicated Internet access services to professionals and
corporations.  During the first quarter of 1998, the Company acquired Channel
Services, LC, to expand its telecommunications products to include wireless
telephone services.  The acquisitions of ConnecTen and Channel Services were
accounted for under the purchase method of accounting. During the first quarter
of 1998, the Company organized Regent Digital Imaging, Inc. to offer digital
printing and prepress services with access available via the Internet. Effective
January 1, 1998, the Company in the ordinary course of business divested its
ownership in all subsidiary companies and re-entered the development stage.

Basis of presentation and going concern uncertainty

The consolidated financial statements of the Company have been prepared assuming
that the Company will continue as a going concern. As of the date of this annual
report, there is substantial doubt regarding our ability to continue as a going
concern as we have not generated sufficient cash flow to grow our business
operations and assume material  commitments. Our future success and  viability,
therefore, are  dependent  upon our ability to generate capital financing.
We are  optimistic  that we will be  successful in  our new business  operations
and  capital  raising  efforts; however, there can be no assurance that we will
be successful in generating revenue or raising additional capital. The failure
to generate sufficient revenues or raise additional capital may have a material
and adverse effect upon the Company and our shareholders.  These consolidated
financial statements do not give effect to any adjustments which would be
necessary should the Company be unable to continue as a going concern and
therefore be required to realize its assets and discharge its liabilities in
other than the normal course of business and at amounts different from those
reflected in the accompanying consolidated financial statements.

Development stage activities

By the end of 1998, the Company had ceased operations and had divested itself
of any interests in subsidiary companies and effective January 1, 1999 had
re-entered the development stage. Accordingly, all of the Company's operating
results and cash flows reported in the accompanying financial statements for
the years 1999 through 2007 are considered to be those related to development
stage activities and represent the 'cumulative from inception' amounts from
its development stage activities reported pursuant to Statements of Financial
Accounting Standards (SFAS) No. 7, Accounting and Reporting by Development
Stage Enterprises.

Subsidiary formation

On March 6, 2007, the Company completed the formation of a new Texas corporation
as a wholly owned subsidiary operating under the name Regent GLSC Technologies,
Inc. ("Regent GLSC").  Regent GLSC was formed to participate in the "global
life science commercialization" process by working with inventors and innovative
research teams focused on the creation of emerging medical products.  Regent
GLSC's focus is the acquisition of equity in new product development and in
future  income streams derived from new products marketed  domestically and
throughout the  world.  Full attention is paid  to the speed of  regulatory
approval, to the status of the product market, and to prospects of competition
that might be encountered in the market. Specific attention is paid to investing
in product groups which have no known rival. In some cases, licensing agreements
will lead to ownership retention of the original development company. In others,
licensing agreements may lead to public stock offerings or to the complete sale
of the development company to an interested suitor.  The strategy includes
sitting on the boards of and shaping policy of the acquired interests to assure
the highest prospect of success.

                                       16
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

Principles of consolidation

The accompanying consolidated financial statements include the general ledger
accounts  of the Company  and its wholly owned  subsidiary, Regent GLSC
Technologies, Inc.  All intercompany account balances have been eliminated
in the consolidation.

Management estimates

The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.

Extinguishment of debt

On September 26, 2006, the Company entered into a settlement agreement whereby
it agreed to issue 64,000 common stock shares, with a fair value of $3,840,
to fully pay and settle its $64,000 note payable and $24,736 of related
accrued interest.  The difference between the fair value of the common stock
shares to be issued and the carrying value of the note payable and accrued
interest has been recognized as a gain on extinguishment of debt in the
accompanying statement of operations.  In addition, $1,011 was recognized as
gain following an adjustment to a previously expensed account payable.

On December 31, 2007, the Company entered into a settlement agreement whereby
the  former transfer agent agreed to settle a disputed accounts receivable
with the Company in the amount $29,666 for a cash payment of $10,000.  As a
result of the settlement, the Company realized a gain of $19,665.  The $10,000
was funded through monies borrowed under promissory notes (Note 4).

Cash and cash flows

For purposes of the consolidated statements of cash flows, cash includes demand
deposits and time deposits with original maturities of less than three months.
None of the Company's cash is restricted.  Also, no taxes were paid during each
of the years ended December 31, 2007 and 2006 and for the period January 1,
1999 through December 31, 2007.  During the years ended December 31, 2007 and
2006 and for period January 1, 1999 through December 31, 2007, interest paid
totaled $400, $200, and $0, respectively.

Settlements and receivable and allowances for uncollectible amounts

The Company's settlement and receivable (Note 6) represent a remaining principal
balance that had not been collected at the balance sheet date for 2006. This re-
ceivable was considered past due based upon applicable facts and circumstances.
At December 31, 2006, the balance of this receivable was reduced by an allowance
for uncollectible amount of $12,892, so that it is reflected in the accompanying
financial statements at its net realizable values of $0 determined from amounts
actually collected previously.

Investments in affiliates

The Company considers estimates regarding fair value of the Company's investment
in preferred stock of MacuCLEAR, Inc. to be a critical accounting policy that
requires significant judgments, assumptions and estimates use in the preparation
of their financial statements.

                                      17
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

On April 17, 2007, Regent GLSC invested $200,000 cash and issued notes payable
for the purchase of 8% convertible preferred stock of MacuCLEAR, Inc. The amount
of MacuCLEAR 8% convertible preferred stock owned by Regent GLSC at December 31,
2007 is convertible into a minority interest of MacuCLEAR common stock. The pre-
ferred stock is accounted for as an investment in equity securities per SFAS No.
115, Accounting for Certain Investments in Debt and Equity Securities, due to
the provisions in the agreement, which gave the Company a non-dilutable conver-
sion right two years after the date of investment. The securities are not held
for trading purposes and are therefore by default and definition, classified as
available-for-sale. There are no definitive marketplace indicators of value that
management can use to determine the fair value of the investment in MacuCLEAR.
Management concluded that the estimated fair value of the securities at December
27, 2007 had not changed from their cost based on quantitative analysis which
considered MacuCLEAR's potential future operating results under a variety of
conditions and consideration of various qualitative factors. Management's
assessment considered that  there have been  no significant changes in the
prospects of MacuCLEAR's business since the original investment and the decision
to make a follow-on investment. As a result, there were no gains or losses
recorded in other comprehensive income for the investment in MacuCLEAR for the
2007 fiscal period.

During September 2006, the FASB issued SFAS No. 157, Fair Value Measurements.
SFAS No. 157 establishes a framework for measuring fair value in GAAP, and
expands disclosures about fair value measurements. SFAS No. 157 is effective
for us as of fiscal 2008. The Company expects the investment in MacuCLEAR to be
measured for fair value based on observable inputs and expects the impact that
SFAS No. 157 will have on its results of operations, financial condition and
liquidity may be significant.  See Note 5.

Property and equipment

Property and equipment is stated at cost less accumulated depreciation.
Depreciation of property and equipment is being provided by the straight-line
method over estimated useful lives of three to seven years. During the years
ended December 31, 2007 and 2006, depreciation expense totaled $0 for each
period, and for the period January 1, 1999 through December 31, 2007, the
depreciation total was $3,762.

Net income (loss) per common share

Basic income (loss) per common share amounts are computed by dividing the net
income (loss) (numerator) by the weighted average number of common stock shares
outstanding (denominator). There are no material dilutive securities; therefore,
no dilutive per share amounts are reflected.  For the years ended December 31,
2007 and 2006, basic income (loss) per common share amounts are based on
5,657,456 and 4,832,317, respectively, weighted average shares of common stock
outstanding.

Unfiled Federal Tax Returns

Since 1998, the Company has not filed any federal tax returns as a result of the
dormant period until 2003 and the continuous losses and net loss carryforwards.
When such filings are made the Company may be subject to failure to file
penalties. No provisions have been made in the financials statements for such
penalties, if any.

                                      18
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

Recent Accounting Pronouncements

During the year ended December 31, 2007, there were several new accounting pro-
nouncements issued by the Financial Accounting Standards Board (FASB) the most
recent of which was Statements on Financial Accounting Standards (SFAS) No. 160,
Noncontrolling interests in Consolidated Financial Statements - an amendment of
ARB No.51.  Each of these pronouncements, as applicable, has been or will be
adopted by the Company. Management does not believe the adoption of any of these
accounting pronouncements has had or will have a material impact on the Com-
pany's financial position or operating results. In the opinion of management,
this statement will have no material effect on the financial statements of the
Company.

In December 2004, the FSAB issued SFAS No. 123R, "Share-Based Payments," re-
vising SFAS No. 123, Accounting for Stock-Based Compensation, and superseding
Accounting Principles Board (APB) Opinion No. 25, "Accounting for Stock Issued
to Employees."  SFAS No. 123R establishes standards for the accounting for
transactions in which an entity exchanges its equity instruments for goods or
services, including obtaining employee services in share-based payment trans-
actions.  SFAS No. 123R applies to all awards granted after the required
effective date and to awards modified, purchased or canceled after that date.
Adoption is effective as of the beginning of the first interim or annual
reporting period that begins after December 15, 2005.  Management does not
believe the adoption of this accounting pronouncement will have a material
impact on the Company's financial position or operating results (Note 6).

Fair value of financial instruments

In accordance with the reporting requirements of SFAS No. 107, Disclosures
About Fair Value of Financial Instruments, the Company calculates the fair
value of its assets and liabilities which qualify as financial instruments
under this Statement and includes this additional information in the notes to
the financial statements when the fair value is different than the carrying
value of those financial instruments. The estimated fair value of settlements
and note receivable are based on management's assessment of net realizable
value and its allowance for uncollectible amounts (see above).  The estimated
fair values of accounts payable approximate their carrying amounts due to the
short maturity of these instruments.  The estimated  fair  value of  the notes
payable also approximates its carrying values because their terms are
comparable to similar lending arrangements in the marketplace.  At December
31, 2007 and 2006 and for the period January 1, 1999 through December 31,
2007, the Company did not have any other financial instruments.

2.      CAPITAL STRUCTURE DISCLOSURES

The Company's capital structure is complex and consists of preferred stock and
a general class of common stock. The Company is authorized to issue 130,000,000
shares of stock, 30,000,000 of which have been designated as preferred shares
with a par value per share of $.10, and 100,000,000 of which have been
designated as common shares with a par value per share of $.01.  In connection
with the settlement of an employment agreement in 1999, 42,876 common stock
shares were returned to the Company and were held in treasury at no cost until
their cancellation in 2005.
                                      19
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

In July, 1995, the Company designated 10,000 shares as Series A Redeemable
Preferred Stock for which no shares were issued and the designation expired in
December, 1998.  No other series, rights or privileges have been designated with
respect to the preferred stock shares.  Each common stock share contains one
voting right and contains the rights to dividends if and when declared by the
Board of Directors.  On March 4, 1998, the shareholders approved a 1 for 6
reverse split of the common stock of the Company.  All share and per share
amounts were retroactively restated in the accompanying financial statements.

On June 29, 1999, the Company entered into a Stock Purchase Agreement with the
Straza Family Limited Partnership, a partnership managed by the father of the
Company's former President, Richard Straza, for stock options and shares of
restricted common stock in exchange for the assignment of notes receivable for
$1,100,000 to the Company.  Although the transaction was never formally closed
as provided for in the agreement, on July 30, 1999, the Company issued
36,046,209 shares of restricted common stock.  The notes receivable were never
assigned to the Company, and on April 5, 2000, the shares were returned to the
Company and cancelled.  The stock options were not issued at any time and the
Stock Purchase Agreement was voided.  The shares outstanding were further
reduced from the return of 500,000 shares as settlement of a note receivable
with Woody, Inc. (Note 6) and the return of 14,429,838 shares from litigation,
all of which have been cancelled (Note 3).  The returned shares represent most
of the shares that were issued in 1999 and 2000 without consideration and
Board approval.  Because these shares were issued for no value and because the
value at the return dates was nominal, no gain or loss is reflected in the
Company's statement of operations.  The shares outstanding also include 64,000
shares issued in 2006 under a settlement and extinguishment of a debt
outstanding (Note 4).

As of December 31, 2007, 5,657,456 shares of common stock are outstanding.
This is an increase over the prior year due to the sale of 3,750 shares as part
of the GHI, Ltd. transaction (Note 6) and the Director Stock Awards (Note 7).

Subsidiary Preferred Stock

On April 18, 2007, Regent GLSC accepted purchase agreements in a total amount
of $150,000.00 received from four purchasers of a private offering of shares
of Series A Convertible Preferred Stock ("Regent GLSC Preferred Stock").  Under
the accepted purchase agreements, the subscribers purchased through a Preferred
Stock Purchase Agreement 30,000 shares of Regent GLSC's Series A Convertible
Preferred Stock at $5.00 per share. The stock was sold under a private placement
offering to sell 25% of the equity of Regent GLSC for $1,250,000 in $50,000
units.  Each unit is convertible into 10,000 shares of common stock of Regent
GLSC plus 0.5% of the outstanding shares of common stock of MacuCLEAR, non-
dilutable for a period of 24 months after the initial closing  of sales of
MacuCLEAR Preferred Stock on April 17, 2007.  Regent GLSC has accepted Preferred
Stock purchase agreements from additional investors in the total amount of
$225,000.  Regent GLSC closed the offering after a sale to two investors for a
total of $50,000 during the first quarter of 2008 (Note 9).

                                      20
<PAGE>
                     REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

3.	COMMITMENTS AND CONTINGENCIES

Leases

The Company currently does not occupy formal office facilities but uses space
on an as needed basis without charge provided by an officer of the Company
and as of 2004 by a business associate otherwise unrelated to the Company.
The fair rental value of this space provided was not and is currently not
material.  At December 31, 2007 and 2006 and for the period January 1, 1999
through December 31, 2007, the Company was not obligated under any
noncancelable operating or capital lease agreements.

Litigation

During 2001, stockholder David Nelson (President of the Registrant beginning
in 2003) initiated a lawsuit against the Company and management of the Company
for issuing shares of common stock without consideration. The case was ordered
for mediation and on  February 27, 2003, the  case was  settled with former
management concurring that 7,331,504 shares were issued without consideration
and should be cancelled.  Also, as part of the mediation settlement, it was
agreed that certain shares previously owned by the father of then President,
Richard Straza and the Straza family members and legal entities (the Straza
Shares) would be returned and cancelled and that the Company would be
indemnified against claims arising from the issuance of the Straza Shares.

On November 2, 2005, W. T. Skip Leake initiated litigation in the 101st State
District Court of Dallas County against the Company and the Company's stock
transfer agent seeking a declaratory judgment for the release of 1,000,000
shares of the 7,331,504 shares which former management states were issued
without consideration.  The Company filed a counter-claim against 35
defendants for a declaratory judgment that all disputed shares are void for
lack of Director approval and failure of consideration and that the 7,331,504
shares and the Straza Shares should be cancelled.  On September 18, 2006,
the Company reached a settlement with W. T. Skip Leake, whereby he effectively
agreed to return 900,000 shares.  As of December 31, 2007, 29 defendants had
returned stock certificates representing 12,362,840 shares and returned lost
certificate resolutions representing 2,771,832 shares, all of which have been
cancelled.  Effective with the filing of this annual report, the Company has
filed a for a default judgment on one defendant.

4.      NOTES PAYABLE

In February 1999, the Company settled an equipment lease obligation and
executed a $64,000 promissory note payable to a vendor.  The note was
non-interest bearing, unsecured and was due March 1, 2004.  On September 26,
2006, the Company entered into a settlement agreement for extinguishment of
the $64,000 and accrued interest in exchange for 64,000 shares of Company
stock (Note 1).

During the third quarter, 2005, the Company borrowed $22,100 under a note
payable to NR Partners, a partnership of which the President is a partner
and Director David Ramsour is a partner.  The note payable is a promissory
note for a maximum amount of $100,000 due on or before July 31, 2008 with
interest at the rate of eight and one half percent. The funds were used to
pay expenses related to professional and transfer agent fees incurred
primarily to bring the Company current with its SEC filings.  During 2007,
the Company has had additional borrowings under the note payable for a total
outstanding at December 31, 2007 of $89,800.  On December 28, 2007, the
Company borrowed $5,000 under a promissory note to Director Phil Ralston,
which note is due and payable on or before December 31, 2008.

                                      21
<PAGE>
                     REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

5.      INVESTMENTS IN AFFILIATES

MacuCLEAR, Inc. investment

On April 17, 2007, Regent GLSC executed a purchase agreement in the amount of
$1,000,000 for the acquisition of 385,356 shares of Series A 8% Preferred Stock
of MacuCLEAR, Inc. ("Preferred Stock"), convertible on a non-dilutable basis
into 20% of the common stock of MacuCLEAR, Inc. for a period of 24 months after
closing.  Regent GLSC acquired its interest through the payment of $200,000 cash
and the execution of a no interest, nonrecourse promissory note in the amount of
$800,000. The principal of this note was payable in two installments. A payment
of $300,000 was tendered on June 29, 2007, and the second payment of $500,000
was due on or before September 30, 2007.  Upon a mutual agreement, the Board of
of Directors of MacuCLEAR voted effective September 30, 2007, to release Regent
GLSC from the second installment without default or recourse and Regent GLSC's
right to purchase an additional 192,678 shares of MacuCLEAR Preferred Stock was
terminated.  The source of the payment of the $500,000 paid for the 192,678
shares of MacuCLEAR Preferred Stock was $325,000 from the sale of 65,000 shares
of Regent GLSC Series A Convertible Preferred Stock (Note 3) and  $50,000 from
NR Partners under a promissory note (Note 4). Since the imputed interest amount
on the discounted note due September 30, 2007, was immaterial, no interest
amount was recorded and following cancellation of the note.

Sale of investment - GHI, Ltd.

On June 29, 2007, Regent GLSC sold 41,250 MacuCLEAR Preferred Stock shares and
3,000 shares of Company common stock to GHI, Ltd. ("GHI") for $150,000.  Each
share of MacuCLEAR Preferred Stock was sold for $3.60 per share and each share
of common stock of Registrant was sold for $.40 per share.  A gain of $41,456
was recognized for the investment sale.  As of December 31, 2007, Regent GLSC
holds title to 151,428 shares of MacuCLEAR Preferred Stock, of which 62,620
shares are beneficially held for the Regent GLSC Preferred Stock holders.

6.  	RELATED PARTY TRANSACTIONS

Settlements with former officers

During June, 1999, the Company executed settlement agreements with the Chairman,
President, General Counsel and the Chief Technical Officer to terminate
each of their employment contracts and the deferred compensation amounts due
thereunder.  The Company issued 50,000 shares of restricted common stock to the
General Counsel in payment of deferred compensation, $5,000 of which was paid
by the Company by the issuance of these shares and the remainder of which was
assumed by the former Chairman in connection with the Company's divestiture of
its subsidiaries. In addition, the Company released the Chief Technical
Officer from his contract in exchange for the stock grant thereunder. Pursuant
thereto, 42,876 shares of restricted common stock were returned to the Company
and in 2005 were cancelled.

The Chairman accepted a $90,000 convertible promissory note for $90,000 of
deferred compensation owed.  At the same time, the promissory note was assigned
to a third party and converted into 900,000 shares of restricted common stock.
The President accepted a $100,000 convertible promissory note and an account
payable of $10,000 for $90,000 of deferred compensation owed and $20,000 of
expense reimbursement for the termination of his employment contract.  In
addition, the President received an option to purchase 100,000 shares of the
Company's restricted common stock at an exercise price of $.25 and expiring
on June 30, 2004.  At the same time, the promissory note was assigned to a
third party and converted into 900,000 shares of restricted common stock.  In
addition, the President is a partner with NR Partners, an entity that has
a loan to the Company (Note 4).

                                       22
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

Settlements receivable, former Chairman

In connection with the Company's 1998 divestiture through a sale in lieu of
foreclosure of its interest in two subsidiaries, the Company received two
receivables from its then Chairman of $20,000 and $27,888.  The receivables
were non-interest bearing, unsecured and due upon demand.  The Company
received repayments of $4,800 in 2000 and $2,420 and $27,888 in 1999,
respectively on such receivables through the payment of Company expenses
by the former Chairman.  Since that time there have been no other payments
on these receivables and they have been fully reserved as uncollectible.

Note receivable (Woody, Inc.)

In 1998, the Company received a $67,000 non-recourse promissory note from
Woody, Inc., a corporation wholly owned by a stockholder, in exchange for
100% of the shares of the stock of Tel1 Communications, Inc.  The note
bears interest, which is payable annually on December 28th, at 6.0 percent,
was due on December 28, 2003 and is unsecured.  No interest or principal has
been paid on this note and it has been considered in default.  Effective
July 31, 2006, Woody, Inc. returned 500,000 shares of common stock of the
Company as full payment and settlement of this note.  As discussed in Note 1
(Settlement and note receivable and allowance for uncollectible amounts),
since this note was fully reduced by an allowance for uncollectible amounts
and no value was assigned to the shares, no gain or loss was reflected in
the Company's statement of operations.

Sale of investment (GHI, Ltd.)

As an inducement for GHI, Ltd. to enter into the purchase of 41,250 shares
of MacuCLEAR Preferred Stock from Regent GLSC, the President of Regent GLSC
pledged 100,000 shares of common stock of MacuCLEAR as a security in the
event of damages, if any, resulting from Regent GLSC's default in the final
payment on the promissory note to MacuCLEAR.  Effective September 30, 2007,
the security interest was released and the sale to GHI, Ltd. finalized
following the termination of the MacuCLEAR promissory note without default as
approved by the Board of Directors of MacuCLEAR.

7.       STOCK OPTIONS AND OTHER GRANTS

Stock options

In 1998, in connection with a private placement of the Company's common shares,
the Company issued 333,333 warrants to purchase restricted common stock at
$1.00 per share and expiring on June 30, 2003.  In 1999, the Company issued to
a director (Note 6) an option to purchase 100,000 shares of the Company's
restricted common stock at an exercise price of $.25 and expiring on June
30, 2004.  Other than the above options and warrants, no other options,
warrants or similar rights have been granted and all options have expired
without execution.

                                       23
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

Restricted stock awards

In December 2007, the Company entered into restricted stock award agreements
with its directors under which it may be required to issue up to 2,000,000
shares of common stock, 500,000 shares to each director. The restricted stock
awards vest over 36 months from the date of first service as a Director which
resulted in the grant of 500,000 shares to the President and 347,223 shares
to the remaining Directors. The remainder vests in increments of 75,000 shares
on June 30 and December 31 of each year beginning in 2008. The Company has
valued the restricted stock grant at $2,000 for tax purposes, being the value
of the shares on the day the agreement was completed. The Company has valued
the shares for book purposes at $20,000, being the par value of the stock.
The total cost of the restricted stock grant will be recognized in the
consolidated statement of operations over an estimated period of 3 years.
For the period ended December 31, 2007, $8,742 has been recognized as
compensation expense.

8.	INCOME TAXES

The Company recognizes deferred tax assets and liabilities based on the
estimated future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases.  In addition, future tax benefits, such
as those from net operating loss carry forwards, are recognized to the
extent that realization of such benefits is more likely than not.  Deferred
tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences
are expected to be recovered or settled.  The effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the
period that includes the enactment date.  At December 31, 2007 the Company
had a deferred tax asset totaling approximately $440,200, which relates
to the Company's cumulative net operating loss carry forward totaling
approximately $1,294,700 and the allowance for uncollectible settlements
and note receivable, which will expire through 2025.  This deferred tax
asset has been fully offset by a valuation reserve.  The Company does not
have any other deferred tax assets or liabilities.

The Tax Reform Act of 1986 imposed substantial restrictions of the utilization
of net operating loss and tax credit carry forwards in the event of an
"ownership change" as defined by the Section 382 of the Internal Revenue Code
of 1986.  If the Company has an "ownership change" as defined by the Internal
Revenue Code of 1986, the Company's ability to utilize the net operating
losses could be reduced.

A reconciliation of income tax expense at the statutory federal rate of 34% to
income tax expense at the Company's effective tax rate for the years ended
December 31, 2007 and 2006 and for the period January 1, 1999 through
December 31, 2007 is as follows:

<TABLE>
<CAPTION>
                                                                                                 Cumulative
                                                                                             Since Re-entering
                                                Year Ended                Year Ended         Development Stage
                                                 12/31/07                  12/31/06           January 1, 1999
                                             ------------------       -------------------    -----------------
<S>                                           <C>                      <C>                    <C>
Tax benefit computed
     at statutory rate				$   2,531               $   18,017              $ ( 48,073)
State income taxes                                    372 	             2,650		  (  7,070)
Expiration of NOL Carryforward                          -                        -                       -
Increase (decrease) in valuation allowance         (2,903)                ( 20,667)               ( 55,142)
                                                 --------                 --------                --------
                                                $       -                $       -               $       -
                                                 =========                =========               =========


</TABLE>

                                       24
<PAGE>
                    REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                            DECEMBER 31, 2007 AND 2006

The Company uses the accrual method of accounting for income tax reporting
purposes.  At December 31, 2007, the significant components of the Company's
deferred tax assets (benefits) and liabilities are summarized.

						 2007
						 ----
	Deferred tax assets:
	  Net operating loss carry forward   $ 440,200
	  Allowance for doubtful accounts            -
	Less valuation allowance              (440,200)
					      ---------
                                                     -
	Deferred tax liabilities:
	  Depreciation differences                   -
                                              ---------
	Net deferred tax assets              $       -
                                              =========


9.  	SUBSEQUENT EVENTS

Sale of investment and subsidiary preferred stock

On February 20, 2008, Regent GLSC sold 10,000 shares of Regent GLSC Preferred
Stock for $5.00 per share as the final sale under the offering originated on
April 17, 2007.  In addition, effective March 7, 2008, Regent GLSC sold 25,000
shares of MacuCLEAR Preferred stock for $100,000.

Loan payment - related parties

During February, 2008, the Company made payments toward the promissory note of
NR Partners totaling $86,520.90 in principal and $8,760.01 in interest.


ITEM 8 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
         FINANCIAL DISCLOSURE

None

ITEM 8A(T) - CONTROLS AND PROCEDURES

Disclosure controls and procedures

As of December 31, 2007, an evaluation was carried out under the supervision
and with the participation of our management, including our Chief Executive
Officer and Chief Financial Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the
"Exchange Act")). Based upon that evaluation, the Chief Executive Officer
and the Chief Financial Officer concluded that the design and operation of
these disclosure controls and  procedures were effective to ensure that
information required to be disclosed by us in the reports that we file or
submit under the  Exchange Act is recorded,  processed, summarized  and
reported within the time periods specified in applicable rules and forms.

Management's report on Internal Control over financial reporting

Our management is responsible for  establishing and  maintaining adequate
internal control over financial  reporting as defined in Rule 13a-15(f) and
15d-15f under the  Securities Exchange Act of 1934. The Company's internal
control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with accounting
principles generally accepted in the United States of America. Because of its
inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate
because of changes in conditions or because the degree of compliance with
policies or procedures may deteriorate.

                                     25
<PAGE>
Under the supervision and with the participation of our management, including
our CEO and CFO, we conducted an assessment of the effectiveness of our
internal control over financial reporting as of December 31, 2007. The
assessment was based on criteria established in the framework Internal Control
- Integrated Framework, issued by the Committee of Sponsoring Organizations of
the Treadway Commission. Based on this assessment, management concluded that
our internal control over financial reporting was effective as of December 31,
2007. This annual report does not include an attestation report of the Company's
registered public accounting firm regarding internal control over financial
reporting. Management's report was not subject to attestation by the Company's
independent registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission that permit the Company to provide only
management's report in this annual report.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting
identified in connection with the evaluation required by Rule 13a-15(d) and
Rule 15d-15(d) of the Exchange Act that occurred during the period covered by
this report that has materially affected, or reasonably likely to materially
affect, the Company's internal control over financial reporting.

                                PART III

ITEM 9 - DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
         COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

The Executive Officers and Directors of the Company and their respective ages as
of December 31, 2007 are as follows:

DIRECTORS

Name of Director:          Age:     Director Since      Other directorships held
-----------------          ----     --------------      ------------------------
David A. Nelson             59        June, 2003            MacuCLEAR, Inc.
Philip G. Ralston           62        June, 2007            MacuCLEAR, Inc.
David L. Ramsour            66        June, 2007                 None

EXECUTIVE OFFICERS

Executive Officer:         Age:         Office:              Officer Since
------------------         ----         -------             --------------
David A. Nelson             59       President, CEO             June, 2003
David L. Ramsour            66         Secretary            December, 2007

David A. Nelson started his professional career with Republic National Bank of
Dallas in 1972.  After four years, he received a leave of absence from Republic
to enter law school and returned to the bank in the Trust Department. Mr. Nelson
left the bank in 1983 as a Vice President after serving in the Trust Department
and the Metropolitan Lending Division.  Beginning in 1983, Mr. Nelson entered
the practice of law in the energy business and remained active in the energy
business through 1992.  From 1989 to 1992, he was the Chairman and CEO of a
public oil and gas company.  He presided over the expansion of oil and gas
proven reserves for four consecutive years, and the company's first three years
of profitability in ten years of previous operations, increasing revenues from
$15,000 per month to $2.5 million annually.  From 1992 through 1998, Mr. Nelson
was President of Regent Technologies, Inc. during which time Regent was active
in the internet services and connectivity business.  In 1998, Regent's internet
assets were acquired by Allegiance Telecom, a NYSE company and Mr. Nelson
returned to the financial services business.  From 1999 to September 2001,
Mr. Nelson was President, CEO and Chairman of Concord Trust Company, a Texas
regulated trust company and a subsidiary of the Baptist Foundation of Texas.
During this same period, he served as a Senior Vice President of the Foundation
with responsibility for charitable gift consulting and trust administration.
Since 2002, he has been active in the areas of alternative investments, private
capital formation and investment management.  In 2003, he was elected President
and CEO of Regent.  At the end of 2007, Mr. Nelson became a full-time employee
of the Company.
                                     26
<PAGE>

Mr. Nelson is a graduate of Baylor University with a BA degree in Mathematics
in 1969 and a Juris Doctor degree from Baylor Law School in 1978.  In 1971, he
completed a Master of Computing Sciences degree from Texas A&M University.
Mr. Nelson has been a licensed attorney in the State of Texas since 1978, and
in 2004  earned the ACCREDITED INVESTMENT FIDUCIARY professional designation,
awarded by the Center for Fiduciary Studies in association with the University
of Pittsburgh.

Philip G. Ralston has spent thirty plus years in the life science industry as a
senior executive, inventor, company founder, venture capitalist, and business
coach. Phil received a solid foundation in product development and technology
commercialization at Baxter Healthcare, as Director of Biomedical Engineering,
a corporate level group focused on strategic projects that advanced the state-
of-the-art. A proven team builder, he was known for his "teamthink" approach to
developing people and started several programs to accelerate team-based product
commercialization. Since leaving Baxter, Mr. Ralston has started four companies,
has been the senior operating executive of two midsize medical device companies,
and for the last decade has been a business coach for several Fortune 500, mid-
size and start-up clients. He has significant hands-on knowledge and experience
in all facets of operations and marketing for pharmaceutical, biotechnology and
biomedical products from start-ups to mature manufacturing entities. Phil has
operated successfully in public, private and non-profit organizations. He holds
18 patents on various medical products, including drug delivery, monitoring and
cardiovascular devices. Phil has proven himself highly effective in assessing
risk and viability probability for start-up life science companies and products.

Mr. Ralston has a Master of Business Administration from the Kellogg School of
Management at Northwestern University, and a Bachelor of Science Degree in
Chemistry from Brigham Young University. He is a charter board member of the
Medical Device Manufacturers Association and currently serves on the advisory
board of the Houston Technology Center and Medici Biomedical Development Center.

David L. Ramsour, PhD, has served as a financial and economic strategist for the
past 35 years. He began his career as Vice President and International Economist
with First National Bank of Dallas and its holding company, First International
Bancshares.  Dr. Ramsour subsequently joined Bank of Hawaii as Senior Vice
President and Chief Economist.  At the Bank of Hawaii, Dr. Ramsour headed the
Bank's division assessing Fed policy, rates and credit and investment conditions
in the US, Europe, Asia and the Pacific, and provided portfolio, market and
project feasibility counsel for the Bank and its clients.  Aside from helping
formulate credit and risk strategies for the Bank, his work involved consulting
with client investor groups from both Asia and the US and advising federal,
state and Pacific Island government bodies on industrial, monetary and fiscal
policies.  Dr. Ramsour left Bancorp Hawaii in 1995 to begin work on behalf of
the Governor of Guam in the development of extensive industrial restructuring
of the Territory's harbor and shipyard resources.  Over the ensuing years, he
has worked as a consultant to a great number of US, Pacific and Asian corporate
and government enterprises and has spoken to international conferences there
and in Europe.  Dr. Ramsour also served on various task forces and policy
committees including three-terms as a member of the American Bankers Association
Council of Economic Advisors in Washington, DC.

Dr. Ramsour is a graduate of Baylor University with a BA and Master's degree.
He was a recipient of graduate fellowships for study at the American University
of Beirut and Columbia University. In 1976, he received his PhD in international
finance from the University of Texas at Dallas.  He has subsequently obtained
other financial and professional designations for his work in financial
management.

                                       27
<PAGE>
Section 16(A) Beneficial Ownership Reporting Compliance

During the 2007 fiscal year there were no individuals who were required to
comply with the reporting requirements under Rule 16A-3 of the Exchange Act and
failed to do so.

Effective March 1, 2006, the Board of Directors adopted a Code of Ethics that
will apply to its principal executive officer, principal financial officer,
principal accounting officer and controller, or persons performing similar
functions.

At present, Regent does not maintain an audit committee, instead the company's
board of directors is responsible to review all audit matters.

ITEM 10 - EXECUTIVE COMPENSATION

The table below summarizes all compensation awarded to, earned by, or paid to
the executive officers of Regent by any person for all services rendered in any
capacity to Regent for the present fiscal year.

<TABLE>
<CAPTION>
                                               Other                  Securities
Name and                                       Annual     Restricted  Underlying              All Other
principal                                      Compen-      Stock      Options/     LTIP       Compen-
position           Year   Salary($)   Bonus   sation($)   Award(s)($)   SARs($)   Payouts($)   sation($)
--------           ----   ---------   -----   ---------   -----------   -------   ----------   ---------
<S>                <C>    <C>         <C>      <C>       <C>         <C>        <C>         <C>

David A. Nelson,     2007    $*         0.00     0.00      5,000.00      0.00       0.00        0.00
President, CEO	     2006    $*         0.00     0.00          0.00      0.00       0.00        0.00
                     2005    $*         0.00     0.00          0.00      0.00       0.00        0.00

Philip G. Ralston,   2007    $*         0.00     0.00      1,305.56      0.00       0.00        0.00
Director

David L. Ramsour,    2007    $*         0.00     0.00      1,166.70      0.00       0.00        0.00
Director, Secretary

Douglas R. Baum,     2007    $*         0.00     0.00      1,000.00      0.00       0.00        0.00
Regent GLSC Director

</TABLE>

----------
*    No compensation.



ITEM 11 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Principal Shareholders

As of December 31, 2007, there are 5,657,456 shares of Common Stock issued
and outstanding.  The following table utilizes the outstanding number as the
denominator in setting forth information  as of the  date of this Annual
Report concerning: (i) each person who is known by us to own beneficially
more than 5% of our outstanding Common Stock; (ii) each of our executive
officers, directors and  key employees; and (iii) all executive officers and
directors as a group.  Common Stock not outstanding but deemed beneficially
owned  by  virtue of the right of an individual to acquire shares within
sixty (60) days is treated as outstanding only when determining the amount
and percentage of Common Stock owned by such individual.  Except as noted,
each person or entity has sole voting and sole investment power with respect
to the shares of Common Stock shown.

                                      28
<PAGE>
<TABLE>
<CAPTION>

<S>               <C>                             <C>  <C>            <C>
Title of Class     Name and Address of                   Amount and     Percent of
                   Beneficial Owner                      Nature of	Class
	                                                 beneficial
                                                         Ownership

Common Stock       David A. Nelson                   (1)  2,464,799        43.57%
                   18 St. Laurent Place
                   Dallas, TX 75225

Common Stock       Philip G. Ralston, Jr.            (2)    130,556         2.31%
                   3417 Grand Mesa Drive
                   Plano, TX 75025

Common Stock       David L. Ramsour                  (3)    116,667         2.06%
                   6807 Hyde Park
                   Dallas, Texas 75231

Common Stock       Douglas R. Baum                   (4)    100,000         1.77%
                   5000 Raffee Cove
                   Austin, Texas 78731

Common Stock	   All officers and directors        (5)  2,812,012        49.70%
		   as a group (1 person)

</TABLE>


(1) David A. Nelson is the President/Chief Executive Officer and a director of
Regent.  He is also the CEO and a director of Regent GLSC.  At the date of the
filing of this report.  This figure includes: (i) 1,750,000 restricted shares
and 621,943 unrestricted shares held of record or beneficially by David A.
Nelson; (ii) 16,667 restricted shares and 76,189 unrestricted shares held
of record by spouse Elaine E. Nelson; and (iii) 175,182 held directly or
beneficially in brokerage accounts.

(2) Philip G. Ralston is a director of Regent and the President and a director
of Regent GLSC.

(3) David L. Ramsour is a director and the Secretary of Regent.

(4) Douglas R. Baum is a director of Regent GLSC, a subsidiary of Registrant.

(5) This figure includes the shares of the officers and directors.  There are no
outstanding options or warrants as of the date of the filing of this report.

                                        29
<PAGE>
ITEM 12 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Straza settlement

On June 29, 1999, the Company entered into a Stock Purchase Agreement with the
Straza Family Limited Partnership, a partnership managed by the father of the
Company's President, Richard Straza, for stock options and shares of restricted
common stock in exchange for the assignment of notes receivable totaling
$1,100,000 to the Company.  Although the transaction was never formally closed
as provided for in the agreement, on July 30, 1999, the Company issued
36,046,209 shares of restricted common stock.  The notes receivable were never
assigned to the Company, and on April 5, 2000, the shares were returned to the
Company and cancelled.  The stock options were not issued at any time and the
Stock Purchase Agreement was voided.  As partial settlement with Straza and
related parties, the Straza Family Limited Partnership was granted 200,000
shares of restricted common stock of the Registrant with the right of the
Company to vote said shares for a period of one year from the date of issuance
on March 13, 2008.

Sale of investment

As an inducement for GHI, Ltd. to enter into the purchase of 41,250 shares
of MacuCLEAR Preferred Stock from Regent GLSC, the President of Regent GLSC
pledged 100,000 shares of common stock of MacuCLEAR as a security in the
event of damages, if any, resulting from Regent GLSC's default in the final
payment on the promissory note to MacuCLEAR.  Effective September 30, 2007,
the security interest has been released and the sale to GHI, Ltd. finalized
following the termination of the MacuCLEAR promissory note without default as
approved by the Board of Directors of MacuCLEAR.

Restricted Stock Awards

On November 26, 2007, the Board of Directors approved Restricted Stock Awards
for each Director as partial consideration for service as Directors of the
Company and a Company subsidiary.  Each grant is for up to 500,000 shares of
the Company's restricted common stock issued as Rule 144 securities. The stock
awards vest over 36 months from the date of first service as a Director which
resulted in the grant of 500,000 shares to the President and 347,223 shares
to the remaining Directors. The remainder vests in increments of 75,000 shares
on June 30 and December 31 of each year beginning in 2008. The Company has
valued the restricted stock grant at $2,000 for tax purposes, being the value
of the shares on the day the agreement was completed. The Company has valued
the shares for book purposes at $20,000, being the par value of the stock.
The total cost of the restricted stock grant will be recognized in the
consolidated statement of operations over an estimated period of 3 years.

ITEM 13 - EXHIBITS, LISTS AND REPORTS ON FORM 8-K

(a)  Exhibits.

     The exhibits required by this item are listed on the Exhibit Index
     attached hereto and are either filed herewith or incorporated herein
     by reference.

(b)  Reports on Form 8-K.

    On March 20, 2007, the Company filed a Current Report on Form 8-K
    reporting a material definitive agreement whereby the Company completed
    the formation of a new Texas corporation as a wholly owned subsidiary
    operating under the name Regent GLSC Technologies, Inc. ("Regent GLSC"),
    and the execution of its initial purchase and sale agreement in the amount
    of $50,000.00 for the subscription by an investor to purchase 10,000 shares
    of Regent GLSC preferred stock under a private placement offering to sell
    25% of the equity of Regent GLSC for $1,250,000.

                                       30
<PAGE>
    On April 26, 2007, the Company filed a Current Report on Form 8-K
    reporting that Regent GLSC Technologies, Inc. ("Regent GLSC"), a wholly
    owned subsidiary of the Registrant, accepted purchase agreements in a total
    amount of $150,000 received from four purchasers of its private offering of
    shares of Series A Convertible Preferred Stock (the "Convertible Preferred
    Stock") at $5.00 per share.  The Company also reported that Regent GLSC
    executed a stock purchase agreement in the amount of $1,000,000 for the
    acquisition of 385,356 shares of Series A Preferred Stock of MacuCLEAR,
    Inc. ("MacuCLEAR"), convertible on a non-dilutable basis into 20% of the
    common stock of MacuCLEAR for a period of 24 months after closing.

    On June 22, 2007, the Company filed a Current Report on Form 8-K
    reporting that effective June 15, 2007, the Board filled two vacancies
    on the Board of Directors with the election of Philip G. Ralston and
    David L. Ramsour, Ph.D.  Philip G. Ralston is the CEO of MacuCLEAR and the
    President of Regent GLSC, a subsidiary of the Registrant.

    On December 11, 2007, the Company filed a Current Report on Form 8-K
    reporting that effective November 26, 2007, the Board had approved
    Restricted Stock Awards for each Director as partial consideration for
    service as Directors of the Company and a Company subsidiary.  The Company
    further reported that each grant is for up to 500,000 shares of the
    Company's restricted common stock issued as Rule 144 securities and that
    the stock awards vest over 36 months from the date of first service as a
    Director which resulted in the grant of 500,000 shares to the President
    and 347,223 shares to the remaining Directors.

    On January 14, 2008, the Company filed a Current Report on Form 8-K
    reporting that the Company had settled all outstanding claims regarding the
    litigation initiated in November, 2005 by W.T. Leake in the 101st State
    District Court of Dallas County against the Company and the stock transfer
    agent.  The Company further reported that it is dismissing its counter-
    claim against 34 defendants which sought a declaratory judgment for the
    cancellation of approximately 16,000,000 shares as void for lack of Director
    approval and failure of consideration.

ITEM 14 - PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following information concerns the aggregate fees billed for each of the
last two fiscal years for professional services rendered by Turner, Stone &
Company, L.L.P., the principal accountants for Regent.

                                          2007            2006
                                          ----            ----
     1. Audit Fees                     $21,010         $13,550
     2. Audit-Related Fees                   0               0
     3. Tax Fees                             0               0
     4. All Other Fees*                      0               0

----------
*    There were no other fees billed to Regent by its principal accountant for
     the last two fiscal years for any products or services not covered in items
     1, 2 or 3 above.

Although Regent has three directors, the Company does not maintain a standing
audit committee. Although the Company does not maintain an audit committee, all
professional services are pre-approved by the Board of Directors, including
the audit fees listed in Item 1.  The balance of the services described in
Items 2 or 3 above are pre-approved only to the extent that discussions are
held with the principal independent accountant for Regent prior to the
commencement of any services by the accountant, during which time all services
to be performed by the accountant on behalf of Regent were outlined.

                                       31
<PAGE>

                                   SIGNATURES

     In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                                REGENT TECHNOLOGIES, INC.


                                            By: /s/ DAVID A. NELSON
                                                --------------------------------
                                                David A. Nelson, President,
                                                CEO and Principal Accounting
                                                Officer

                                          Date: March 31, 2008
                                                --------------------------------

                                       32
<PAGE>


                             EXHIBIT INDEX

Exhibit                 Description of Exhibit
No.

3.1   Certificate of Incorporation.  Incorporated by reference to the Company's
      Registration Statement which became effective November 18, 1980 (File
      Number 2-69087).

3.2   Restated Articles of Incorporation of Regent Technologies, Inc.;
      Incorporated by references to  Regent Petroleum Corporation Proxy
      Statement for Special Meeting of Shareholders held January 26, 1988,
      dated December 30, 1987.

3.3   Bylaws of Regent Technologies, Inc. as amended; Incorporated by references
      to Regent Petroleum Corporation Proxy Statement for Special Meeting of
      Shareholders held January 26, 1988, dated December 30, 1987.

3.4   Code of Ethics; adopted by a resolution of the Board of Directors dated
      March 14, 2006 with an effective date of March 1, 2006.

21    List of subsidiaries - Regent GLSC Technologies, Inc.

31.1  Certification of Chief Executive Officer and Principal Accounting Officer

32.1  Certification of Chief Executive Officer and Principal Accounting Officer